Holen Sie sich die Stockscreener-App
2.24
3.70%
0.08
Handel nachbörslich:
2.19
-0.05
-2.23%
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat
Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada
Adagene reports new findings at SITC meeting - Investing.com India
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau
Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire
Adagene's ADG126 Shows Breakthrough Results in Cancer Treatment, Outperforms Ipilimumab | ADAG Stock News - StockTitan
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene reports promising cancer therapy results - Investing.com
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - MSN
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World
Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire
Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World
Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in June - Defense World
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Yahoo Finance
Adagene To Participate In The SVB Leerink 11th Annual Global Healthcare Conference - Barchart
Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast - Defense World
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - Quantisnow
Adagene Announces Updates to its Board of Directors - Quantisnow
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million - Quantisnow
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Quantisnow
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference - Quantisnow
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Quantisnow
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 - Quantisnow
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody ... - Quantisnow
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate - Quantisnow
Adagene (NASDAQ:ADAG) Given Buy Rating at HC Wainwright - Defense World
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):